e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Ceremony for the ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension (financially supported by Actelion) followed by Symposium: Drug-induced pulmonary arterial hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cancer treatment in pulmonary hypertension: cause or cure?
H.J. Bogaard (Amsterdam, Netherlands)
Source:
Annual Congress 2013 –Ceremony for the ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension (financially supported by Actelion) followed by Symposium: Drug-induced pulmonary arterial hypertension
Session:
Ceremony for the ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension (financially supported by Actelion) followed by Symposium: Drug-induced pulmonary arterial hypertension
Session type:
Symposium
Number:
3004
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H.J. Bogaard (Amsterdam, Netherlands). Cancer treatment in pulmonary hypertension: cause or cure?. Annual Congress 2013 –Ceremony for the ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension (financially supported by Actelion) followed by Symposium: Drug-induced pulmonary arterial hypertension
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Thrombo-embolic pulmonary hypertension: which treatment should we choose? / Hypertension pulmonaire thrombo-embolique: quel traitement choisir ?
Source: International Congress 2018 – French Programme 2018: Part II
Year: 2018
Diagnosis and treatment of pulmonary hypertension in COPD patients: how far should we go?
Source: International Congress 2019 – Lung vessels in COPD: it is time to take them seriously!
Year: 2019
Interventional treatment of pulmonary hypertension: where are we now?
Source: Virtual Congress 2020 – Breathing disorders and cardiovascular diseases
Year: 2020
Treatment of pulmonary hypertension due to COPD: can we really hope in better?
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Chronic thromboembolic pulmonary hypertension: do we need a new definition?
Source: Eur Respir J 2014; 44: 1401-1403
Year: 2014
Pulmonary hypertension and chronic lung disease: where are we headed?
Source: Eur Respir Rev, 28 (153) 190065; 10.1183/16000617.0065-2019
Year: 2019
Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Lung cancer in patient with chronic obstructive pulmonary disease (comorbidity by smokers-a cumulative effect of exogenic and endogenic factors? Part II)
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options
Source: Eur Respir Rev 2009; 18: 24-28
Year: 2009
Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Chronic thromboembolic pulmonary hypertension and splenectomy: Is there a link?
Source: Eur Respir J 2003; 22: Suppl. 45, 218s
Year: 2003
Diabetes mellitus as cause of treatment failure and relapses of pulmonary tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 311s
Year: 2001
Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Pulmonary hypertension in the elderly: a different disease?
Source: Breathe 2016; 12: 43-49
Year: 2016
PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Severe pulmonary hypertension in lung disease: phenotypes and response to treatment
Source: Eur Respir J 2015; 46: 1378-1389
Year: 2015
Surgical treatment of chronic thromboembolic pulmonary hypertension: a single centre experience
Source: Eur Respir J 2001; 18: Suppl. 33, 14s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept